The immunohistochemistry (IHC) 22C3 FDA-approved companion diagnostic assay for evaluation of PD-L1 protein expression in NSCLC tissue biopsy specimens is indicated for selecting patients for pembrolizumab immunotherapy [7]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.